KR20100119804A - 부정맥 치료용 약제의 제조를 위한 라놀라진의 용도 - Google Patents

부정맥 치료용 약제의 제조를 위한 라놀라진의 용도 Download PDF

Info

Publication number
KR20100119804A
KR20100119804A KR1020107021063A KR20107021063A KR20100119804A KR 20100119804 A KR20100119804 A KR 20100119804A KR 1020107021063 A KR1020107021063 A KR 1020107021063A KR 20107021063 A KR20107021063 A KR 20107021063A KR 20100119804 A KR20100119804 A KR 20100119804A
Authority
KR
South Korea
Prior art keywords
ranolazine
compound
apd
administration
lower alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1020107021063A
Other languages
English (en)
Korean (ko)
Inventor
루이즈 벨라디넬리
찰스 안첼레비치
브렌트 블랙번
Original Assignee
씨브이 쎄러퓨틱스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 씨브이 쎄러퓨틱스, 인코포레이티드 filed Critical 씨브이 쎄러퓨틱스, 인코포레이티드
Publication of KR20100119804A publication Critical patent/KR20100119804A/ko
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020107021063A 2002-04-04 2003-04-04 부정맥 치료용 약제의 제조를 위한 라놀라진의 용도 Abandoned KR20100119804A (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US37015002P 2002-04-04 2002-04-04
US60/370,150 2002-04-04
US40829202P 2002-09-05 2002-09-05
US60/408,292 2002-09-05
US42258902P 2002-10-30 2002-10-30
US60/422,589 2002-10-30

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR10-2004-7015749A Division KR20040099395A (ko) 2002-04-04 2003-04-04 부정맥 치료용 약제의 제조를 위한 라놀라진의 용도

Publications (1)

Publication Number Publication Date
KR20100119804A true KR20100119804A (ko) 2010-11-10

Family

ID=29255318

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020107021063A Abandoned KR20100119804A (ko) 2002-04-04 2003-04-04 부정맥 치료용 약제의 제조를 위한 라놀라진의 용도
KR10-2004-7015749A Ceased KR20040099395A (ko) 2002-04-04 2003-04-04 부정맥 치료용 약제의 제조를 위한 라놀라진의 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR10-2004-7015749A Ceased KR20040099395A (ko) 2002-04-04 2003-04-04 부정맥 치료용 약제의 제조를 위한 라놀라진의 용도

Country Status (19)

Country Link
US (2) US20030220344A1 (enExample)
EP (3) EP1930007B1 (enExample)
JP (1) JP4608217B2 (enExample)
KR (2) KR20100119804A (enExample)
CN (2) CN101843619A (enExample)
AT (2) ATE397932T1 (enExample)
AU (3) AU2003230810B2 (enExample)
CA (1) CA2481192C (enExample)
CY (1) CY1110400T1 (enExample)
DE (2) DE60332975D1 (enExample)
DK (2) DK1930007T3 (enExample)
ES (2) ES2345573T3 (enExample)
IL (1) IL197406A0 (enExample)
MX (1) MXPA04009637A (enExample)
NO (1) NO330953B1 (enExample)
NZ (1) NZ535610A (enExample)
PT (2) PT1490066E (enExample)
SI (2) SI1930007T1 (enExample)
WO (1) WO2003086401A1 (enExample)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030220344A1 (en) * 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias
US8822473B2 (en) * 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
US20040063717A1 (en) * 2002-05-21 2004-04-01 Andrew Wolff Method of treating diabetes
WO2005061470A1 (en) * 2003-12-18 2005-07-07 Cv Therapeutics, Inc. 1-akan-2-ol substituted piperazine and piperidine compounds
SG156681A1 (en) * 2004-11-09 2009-11-26 Cv Therapeutics Inc Use of ranolazine in combination with at least one remodeling agent for reversing left ventricular remodeling in the treatment of heart failure
KR20070093988A (ko) * 2005-01-06 2007-09-19 씨브이 쎄러퓨틱스, 인코포레이티드 라놀라진 함유 서방성 약제학적 제형물
US20060263427A1 (en) * 2005-05-03 2006-11-23 Roberts Richard H Quinine formulations
US20080153840A1 (en) * 2006-12-21 2008-06-26 Luiz Belardinelli Reduction of cardiovascular symptoms
CA2677931A1 (en) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Use of ranolazine for the treatment of cardiovascular diseases
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
CA2678325A1 (en) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Use of ranolazine for the treatment of non-coronary microvascular diseases
JP2010518170A (ja) * 2007-02-13 2010-05-27 ギリアード・パロ・アルト・インコーポレイテッド 冠微小血管疾患の処置のためのラノラジンの使用
WO2008116083A1 (en) * 2007-03-22 2008-09-25 Cv Therapeutics, Inc. Use of ranolazine for elevated brain-type natriuretic peptide
EA200971073A1 (ru) * 2007-05-31 2010-08-30 Джилид Пало Альто, Инк. Применение ранолазина при повышенном уровне натрийуретического пептида мозгового типа
WO2009100380A1 (en) * 2008-02-06 2009-08-13 Cv Therapeutics, Inc. Use of ranolazine for treating pain
WO2010028173A2 (en) * 2008-09-04 2010-03-11 Gilead Palo Alto, Inc. Method of treating atrial fibrillation
WO2010074807A1 (en) * 2008-10-30 2010-07-01 Gilead Palo Alto, Inc. 3, 4-dihydroquinolin-2 ( 1h ) -one derivatives as sodium channel modulators
JP2012526848A (ja) * 2009-05-14 2012-11-01 ギリアード サイエンシーズ， インコーポレイテッド Ｃｎｓ障害の治療のためのラノラジン
WO2014037832A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment of epilepsy and neurological diseases
CN104350041A (zh) 2012-05-07 2015-02-11 塞利克斯比奥私人有限公司 用于治疗神经系统疾病的组合物和方法
WO2013167990A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of depression
CA2873093A1 (en) 2012-05-07 2013-11-14 Cellixbio Private Limited Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
WO2013167991A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic disorders
WO2013168023A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of parkinson's disease
US9403826B2 (en) 2012-05-08 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory disorders
WO2013168025A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of blood clotting disorders
US9434704B2 (en) 2012-05-08 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of neurological degenerative disorders
US9499527B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of familial amyloid polyneuropathy
US9499526B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
US9573927B2 (en) 2012-05-10 2017-02-21 Cellix Bio Private Limited Compositions and methods for the treatment of severe pain
WO2013168001A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
US9242939B2 (en) 2012-05-10 2016-01-26 Cellix Bio Private Limited Compositions and methods for the treatment of respiratory disorders
WO2013168011A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of chronic pain
US9339484B2 (en) 2012-05-10 2016-05-17 Cellix Bio Private Limited Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
US9346742B2 (en) 2012-05-10 2016-05-24 Cellix Bio Private Limited Compositions and methods for the treatment of fibromyalgia pain
WO2013168002A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological conditions
WO2013168016A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
WO2013168015A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of asthma and allergy
WO2013167997A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
US9315461B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
WO2013175347A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
US9492409B2 (en) 2012-05-23 2016-11-15 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
NZ701832A (en) 2012-05-23 2016-08-26 Cellix Bio Private Ltd Compositions and methods for treatment of inflammatory bowel disease
WO2013175377A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of mucositis
SG11201407322QA (en) 2012-05-23 2014-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of multiple sclerosis
WO2013175344A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2014020480A2 (en) 2012-08-03 2014-02-06 Mahesh Kandula Compositions and methods for the treatment migraine and neurologic diseases
WO2014027262A2 (en) * 2012-08-14 2014-02-20 Mahesh Kandula Compositions and methods for the treatment angina and cardiovascular conditions
WO2014037833A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment inflammation and lipid disorders
AU2013311349A1 (en) 2012-09-08 2014-11-27 Cellixbio Private Limited Compositions and methods for treatment of inflammation and lipid disorders
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
AU2014276346A1 (en) 2013-06-04 2015-12-24 Cellixbio Private Limited Compositions and methods for the treatment of diabetes and pre-diabetes
CN105611931A (zh) * 2013-08-01 2016-05-25 吉利德科学公司 治疗长qt综合征的化合物和方法
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
EP3240779B1 (en) 2014-09-26 2020-10-28 Cellixbio Private Limited Compositions and methods for the treatment of epilepsy and neurological disorders
EP3201168B1 (en) 2014-09-29 2020-03-18 Cellix Bio Private Limited Compounds and compositions for the treatment of multiple sclerosis
EP3212626B1 (en) 2014-10-27 2018-11-07 Cellix Bio Private Limited Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
CN110845355A (zh) 2015-01-06 2020-02-28 塞尔利克斯生物私人有限公司 用于治疗炎症和疼痛的组合物和方法
KR101617683B1 (ko) * 2015-01-09 2016-05-03 연세대학교 산학협력단 부정맥 치료제 효과 평가 시스템 및 방법
TW201717919A (zh) 2015-07-02 2017-06-01 國際藥品股份公司 雷諾多重壓縮錠劑
WO2018001582A1 (en) 2016-06-30 2018-01-04 Interquim, S.A. Ranolazine multiple compressed tablets
CN116808039A (zh) * 2023-03-27 2023-09-29 河南中医药大学第一附属医院 青藤碱在制备钾离子、钠离子通道抑制剂中的应用
WO2025010429A1 (en) * 2023-07-06 2025-01-09 The General Hospital Corporation Method and apparatus for evaluating cardiac function

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) * 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US4567264A (en) * 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
US5364620A (en) * 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) * 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) * 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US4902514A (en) * 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
NZ247044A (en) * 1989-06-23 1997-04-24 Syntex Usa Inc Substituted For Use of ranolazine and related piperazine derivatives to treat tissue affected by muscle and neuronal damage, including transplant tissue
JPH03141258A (ja) * 1989-10-25 1991-06-17 Kowa Co 新規なピペラジン誘導体
ATE211135T1 (de) * 1993-09-24 2002-01-15 Univ British Columbia Aminocyclohexylester und ihre anwendung
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
CN1227004C (zh) * 2000-02-18 2005-11-16 Cv治疗公司 治疗充血性心力衰竭的部分脂肪酸氧化抑制剂
US6677336B2 (en) * 2000-02-22 2004-01-13 Cv Therapeutics, Inc. Substituted piperazine compounds
WO2001089554A2 (en) * 2000-05-19 2001-11-29 Bionebraska, Inc. Treatment of acute coronary syndrome with glp-1
AU2001277938A1 (en) * 2000-07-21 2002-02-05 Cv Therapeutics, Inc. Method for treating angina
US6573264B1 (en) * 2000-10-23 2003-06-03 Cv Therapeutics, Inc. Heteroaryl alkyl piperazine derivatives
US20030220344A1 (en) * 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias
US20080109040A1 (en) * 2002-04-04 2008-05-08 Luiz Belardinelli Method of treating arrhythmias

Also Published As

Publication number Publication date
EP2198866A1 (en) 2010-06-23
AU2011202135A1 (en) 2011-05-26
PT1930007E (pt) 2010-08-17
EP1930007B1 (en) 2010-06-09
US20100004255A1 (en) 2010-01-07
MXPA04009637A (es) 2005-07-14
DK1490066T3 (da) 2008-10-13
AU2003230810B2 (en) 2009-02-26
SI1490066T1 (sl) 2008-10-31
SI1930007T1 (sl) 2010-08-31
EP1490066A1 (en) 2004-12-29
CN101843619A (zh) 2010-09-29
CA2481192A1 (en) 2003-10-23
PT1490066E (pt) 2008-07-22
ES2345573T3 (es) 2010-09-27
AU2009201065A1 (en) 2009-04-09
DK1930007T3 (da) 2010-08-30
KR20040099395A (ko) 2004-11-26
CY1110400T1 (el) 2015-04-29
NO20044783L (no) 2004-11-03
AU2003230810A1 (en) 2003-10-27
DE60321550D1 (de) 2008-07-24
IL197406A0 (en) 2011-07-31
AU2009201065B2 (en) 2011-07-21
US20030220344A1 (en) 2003-11-27
ES2304507T3 (es) 2008-10-16
HK1120390A1 (en) 2009-04-03
CN100548300C (zh) 2009-10-14
EP1930007A1 (en) 2008-06-11
NO330953B1 (no) 2011-08-22
WO2003086401A1 (en) 2003-10-23
ATE397932T1 (de) 2008-07-15
JP2005528393A (ja) 2005-09-22
CA2481192C (en) 2012-07-03
JP4608217B2 (ja) 2011-01-12
DE60332975D1 (de) 2010-07-22
NZ535610A (en) 2006-05-26
CN1646127A (zh) 2005-07-27
ATE470445T1 (de) 2010-06-15
EP1490066B1 (en) 2008-06-11

Similar Documents

Publication Publication Date Title
KR20100119804A (ko) 부정맥 치료용 약제의 제조를 위한 라놀라진의 용도
ES2540093T3 (es) Método para tratar la fibrilación auricular
DE69431568T2 (de) Inhibierung der migration und proliferation glatter muskeln mit hydroxycarbazolverbindungen
US6103741A (en) Analgesic agent and its use
JP2010514696A (ja) 心血管症状の低減
US20120046299A1 (en) Method of treating arrhythmias
KR20060100440A (ko) 각결막 장해 치료제
US20100105695A1 (en) Method for enhancing insulin secretion
KR20110042344A (ko) 뇌졸중 또는 일과성 허혈 발작을 예방하기 위한 약제의 제조에서의 드로네다론의 용도
RU2406499C2 (ru) Профилактическое или терапевтическое средство для лечения кератоконъюнктивитных нарушений
HK1145438A (en) Use of ranolazine for the preparation of a medicament for the treatment of arrhythmias
HK1120390B (en) Use of ranolazine for the preparation of a medicament for the treatment of early afterdepolarisations (eads)
ZA200407972B (en) Use of ranolazine for the preparation of a medicament for the treatment of arrhythmias
KR20070053283A (ko) 각결막장해 치료제
KR20080074128A (ko) 각결막 장애 치료제

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20100920

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20101224

Patent event code: PE09021S01D

AMND Amendment
E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20111128

Patent event code: PE09021S02D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20120713

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20111128

Comment text: Final Notice of Reason for Refusal

Patent event code: PE06011S02I

Patent event date: 20101224

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20120816

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20120713

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20121024

Appeal identifier: 2012101007353

Request date: 20120816

PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20120816

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20120816

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20120221

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20110422

Patent event code: PB09011R02I

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

Patent event date: 20121024

Comment text: Decision to Grant Registration

Patent event code: PB07012S01D

Patent event date: 20120918

Comment text: Transfer of Trial File for Re-examination before a Trial

Patent event code: PB07011S01I

NORF Unpaid initial registration fee
PC1904 Unpaid initial registration fee